公开(公告)号：US20220249490A1

公开(公告)日：2022-08-11

申请号：US17505364

申请日：2021-10-19

申请人： The Trustees of the University of Pennsylvania

发明人： Daniel Sterman ,  Steven Albelda

IPC分类号： A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  A61K31/415 ,  A61K31/7068 ,  A61K35/761 ,  C12N15/86 ,  C07K14/47 ,  A61K38/21 ,  A61K31/635 ,  A61K31/555 ,  A61K33/243 ,  A61K9/00 ,  A61K39/12 ,  A61K39/395

摘要： Gene therapy based combination therapy for malignant pleural mesothelioma (“MPM”) that is resistant to or recurrent after chemotherapy employing a viral vector containing a human interferon transgene, followed by standard first- or second-line cytotoxic chemotherapy. Overall survival rate was significantly higher than historical controls in the second-line group.